Leukos Biotech, S. L.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Leukos Biotech, S. L. - overview
Established
2015
Location
Barcelona, -, Spain
Primary Industry
Pharmaceuticals
About
Leukos Biotech is a biopharmaceutical company focused on developing innovative therapies for tumors, including hematological malignancies and solid tumors, aiming to enhance patient treatment outcomes. Founded in 2015 in Barcelona, Spain, Leukos Biotech specializes in biopharmaceuticals targeting cancer treatment. The company’s latest funding round occurred on September 21, 2016, led by Inveready Asset Management, raising EUR 3. 5 million.
The CEO is Luis Ruiz-Avila, and the founder is Ruth Risueño. Leukos Biotech specializes in developing innovative biopharmaceuticals aimed at treating a diverse range of tumors, including hematological malignancies and solid tumors. Their flagship product, LB208, is a first-in-class therapeutic candidate designed to target specific pathways involved in tumor growth and proliferation. These products are directed toward healthcare providers such as hospitals and specialized oncology clinics, particularly in North America and Europe, addressing the need for advanced therapeutic interventions in oncology.
In 2023, Leukos Biotech reported revenue of EUR 349,289. 60, with an EBITDA of EUR -74,746. 90, indicating the company's financial performance during that fiscal year is tied to its strategic partnerships and product sales. Leukos Biotech plans to utilize the EUR 3.
5 million raised in its most recent financing round to support the continued development of LB208 and potentially launch new therapeutic candidates. The company targets expanding its market presence in North America and Europe by 2025, enhancing accessibility to innovative cancer treatments through strategic partnerships with healthcare institutions.
Current Investors
Inveready Asset Management
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.leukosbiotech.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Leukos Biotech, S. L. - timeline of key events
Leukos Biotech, S. L. - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 304,625 | 591,317 | 585,750 | 955,732.8 | 571,876.4 | - | - | - |
| % Revenue Growth (YoY) | - | - | 94.1% | (0.9%) | 63.2% | (40.2%) | - | - | - |
| EBITDA (USD) | (19,246.2) | 19,688.2 | 17,446.4 | (20,824.4) | 266,910.3 | 113,304.3 | - | - | - |
| Operating Income (USD) | (19,246.2) | 19,539.2 | 13,032.7 | (27,972.6) | 259,341.6 | 99,661.5 | - | - | - |
| Operating Margin | - | 6.4% | 2.2% | (4.8%) | 27.1% | 17.4% | - | - | - |
| % EBITDA Margin | - | 6.5% | 3.0% | (3.6%) | 27.9% | 19.8% | - | - | - |
| NET Income (USD) | (14,454.5) | 14,783.2 | 4,581.2 | (48,380.1) | 199,061 | 77,831.1 | - | - | - |
| % Net Margin | - | 4.9% | 0.8% | (8.3%) | 20.8% | 13.6% | - | - | - |
Leukos Biotech, S. L. - employee data
Leukos Biotech, S. L. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman of the Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.